137 related articles for article (PubMed ID: 17083269)
1. The effect of moxonidine on endothelial dysfunction in metabolic syndrome.
Topal E; Cikim AS; Cikim K; Temel I; Ozdemir R
Am J Cardiovasc Drugs; 2006; 6(5):343-8. PubMed ID: 17083269
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
3. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Sharma AM; Wagner T; Marsalek P
J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
[TBL] [Abstract][Full Text] [Related]
4. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
5. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
Haenni A; Lithell H
J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
[TBL] [Abstract][Full Text] [Related]
6. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
Masajtis-Zagajewska A; Majer J; Nowicki M
Hypertens Res; 2010 Apr; 33(4):348-53. PubMed ID: 20139920
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
Abellán J; Leal M; Hernández-Menárguez F; García-Galbis JA; Martínez-Pastor A; de Vinuesa SG; Luño J
Kidney Int Suppl; 2005 Jan; (93):S20-4. PubMed ID: 15613062
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
Ernsberger P; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Friedman JE
J Pharmacol Exp Ther; 1999 Jan; 288(1):139-47. PubMed ID: 9862764
[TBL] [Abstract][Full Text] [Related]
9. Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
Kaaja R; Kujala S; Manhem K; Katzman P; Kibarskis A; Antikainen R; Ylihärsilä H; Erkkola R; Tuomilehto J
Int J Clin Pharmacol Ther; 2007 Jul; 45(7):394-401. PubMed ID: 17725246
[TBL] [Abstract][Full Text] [Related]
10. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women.
Ebinç H; Ozkurt ZN; Ebinç FA; Ucardag D; Caglayan O; Yilmaz M
J Int Med Res; 2008; 36(1):80-7. PubMed ID: 18230271
[TBL] [Abstract][Full Text] [Related]
11. Selective imidazoline agonist moxonidine in obese hypertensive patients.
Sanjuliani AF; de Abreu VG; Francischetti EA
Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
[TBL] [Abstract][Full Text] [Related]
12. Weight reduction versus antihypertensive drug therapy in obese men with high blood pressure: effects upon plasma insulin levels and association with changes in blood pressure and serum lipids.
Fagerberg B; Berglund A; Andersson OK; Berglund G
J Hypertens; 1992 Sep; 10(9):1053-61. PubMed ID: 1328365
[TBL] [Abstract][Full Text] [Related]
13. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P
Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453
[TBL] [Abstract][Full Text] [Related]
14. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
15. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
16. Moxonidine: a review of its use in essential hypertension.
Fenton C; Keating GM; Lyseng-Williamson KA
Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
[TBL] [Abstract][Full Text] [Related]
17. [The influence of diet with reduction in calorie intake on metabolic syndrome parameters in obese subjects with impaired glucose tolerance].
Polovina S; Micić D
Med Pregl; 2010; 63(7-8):465-9. PubMed ID: 21446131
[TBL] [Abstract][Full Text] [Related]
18. [Correction of endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus during combined antihypertensive therapy].
Statsenko ME; Derevianchenko MV
Ter Arkh; 2014; 86(8):90-3. PubMed ID: 25306751
[TBL] [Abstract][Full Text] [Related]
19. [Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes].
Minushkina LO
Kardiologiia; 2011; 51(4):74-8. PubMed ID: 21623724
[TBL] [Abstract][Full Text] [Related]
20. Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome.
Kseneva SI; Borodulina EV; Semiglazova TA; Kulakova NV; Tarasova IV; Trifonova OJ; Gridneva TD; Udut VV
Bull Exp Biol Med; 2011 Aug; 151(4):400-4. PubMed ID: 22448351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
